| Ytd | -2.44% | |
| 1y | 8.50% |
| Open | 5.73 | Prev Close | 5.71 | Low | 5.72 | High | 6.00 | Mkt Cap | 566.69M |
| Vol | 1.63M | Avg Vol | 1.63M | EPS | -4.31 | P/E | N/A | Forward P/E | 71.53 |
| Beta | 1.89 | Short Ratio | 4.83 | Inst. Own | 103.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 4.50 | 200-d Avg | 5.80 | 1yr Est | 19.41 |
MYGN News
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend i
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analys
Myriad Genetics Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price tar
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
Myriad Genetics (NASDAQ:MYGN) sees FY2026 sales of $860.000 million-$880.000 million vs $867.455 mil
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.04 per share which beat the analyst
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Piper Sandler analyst Dave Weiner maintains Myriad Genetics (NASDAQ:MYGN) with a Overweight and l
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medici
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medici
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
TD Cowen analyst Dan Brennan maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and raises the p
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and raises the price tar
Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs
Myriad Genetics (NASDAQ:MYGN) reported quarterly sales of $205.700 million which beat the analyst co
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
US stock futures rose on Wed. after falling on Thurs. Trump threatened tariffs on imported pharma up
After posting second-quarter results that beat revenue and EPS estimates and raising its 2025 guidan
Myriad Genetics (NASDAQ:MYGN) affirms FY2025 Adj EPS guidance from $(0.02)-$0.02 to $(0.02)-$0.02 vs
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.05 per share which beat the analyst
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
Scotiabank analyst Sung Ji Nam downgrades Myriad Genetics (NASDAQ:MYGN) from Sector Outperform to
Piper Sandler analyst Dave Weiner maintains Myriad Genetics (NASDAQ:MYGN) with a Overweight and l